Telix Pharmaceuticals Limited reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported sales was AUD 175 million compared to AUD 101.28 million a year ago. Net income was AUD 17.97 million compared to net loss of AUD 8.49 million a year ago.

Basic earnings per share from continuing operations was AUD 0.0555 compared to basic loss per share from continuing operations of AUD 0.0268 a year ago. Diluted earnings per share from continuing operations was AUD 0.0542 compared to diluted loss per share from continuing operations of AUD 0.0268 a year ago.